Endostatin may stop the progression of atherosclerosisBMJ 1999; 318 doi: https://doi.org/10.1136/bmj.318.7190.1030b (Published 17 April 1999) Cite this as: BMJ 1999;318:1030
- Scott Gottlieb
- New York
The experimental drug endostatin, which is being developed for its ability to shrink cancerous tumours by inhibiting the development of new blood vessels, is also showing promise in stopping atherosclerosis.
Researchers have found that endostatin significantly reduced atherosclerosis in genetically susceptible mice. In the 16 week experiment …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial